Pricing Log in Create free account
Friday 6 November 2026 Export TGTX’s income statement to Excel — free account

TG Therapeutics, Inc.

TGTX Healthcare Biotechnology

TG Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $616.3 million, up 87.3% from fiscal 2024.

Revenue
+70.3%
EPS
−73.7%
Free cash flow
+427.1%
Total debt
+204.2%

Quarter to June 2026, against a year earlier

59.60 1.62 +2.79%
Market cap
$8.9B
P/E
19.6×
Fwd P/E
62.4×
Dividend yield
—
F-score
5/9
Altman Z
6.29
Beneish M
0.80
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

TG Therapeutics, Inc. 10-K filed Feb 27, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed · accepted 5:05 PM ET · Document on sec.gov · Filing index

Red flags

  • Profit ahead of cash

    TG Therapeutics, Inc.’s net income ran ahead of its operating cash flow for a second year, by 44.4% of total assets

    10-K filed · The filing · sec.gov

What changed

Item 1, Business Item 1A, Risk Factors Item 7, Management’s Discussion and Analysis

Item 7, Management’s Discussion and Analysis, against the 10-K filed Mar 3, 2025: 54 added · 22 removed · 29 modified; 4 with only figures updated